Protalix BioTherapeutics (PLX) EBIAT (2010 - 2026)
Protalix BioTherapeutics' quarterly EBIAT came in at $18.3 million in Q1 2026, up 606.13% year-on-year from $2.6 million in Q1 2025, and up 432.79% quarter-over-quarter from -$5.5 million in Q4 2025.
Protalix BioTherapeutics has reported EBIAT for 17 years, with the latest figure at $18.3 million in Q1 2026.
- For the quarter ending Q1 2026, EBIAT rose 606.13% year-over-year to $18.3 million; the trailing twelve-month figure through Mar 2026 stood at $15.3 million (up 292.32% YoY), and the FY2025 full-year result was -$6.6 million, down 325.24% from the prior year.
- EBIAT for Q1 2026 stood at $18.3 million, up from -$5.5 million in the prior quarter.
- The five-year high for EBIAT was $19.3 million in Q2 2023, with the low at -$6.0 million in Q4 2023.
- Average EBIAT over 5 years is $472352.9, with a median of -$2.3 million recorded in 2022.
- Year-over-year, EBIAT sank 184.76% in 2025 and surged 606.13% in 2026.
- Tracing PLX's EBIAT over 5 years: stood at -$3.7 million in 2022, then slumped by 61.6% to -$6.0 million in 2023, then surged by 207.45% to $6.5 million in 2024, then slumped by 184.76% to -$5.5 million in 2025, then surged by 432.79% to $18.3 million in 2026.
- The last three EBIAT figures came in at $18.3 million (Q1 2026), -$5.5 million (Q4 2025), and $2.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 30.90 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Protalix BioTherapeutics | 164.49 Mn | 153.70 Mn | 29.62 Mn | 18.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18.32 Mn |
| Dec 31, 2025 | -5.50 Mn |
| Sep 30, 2025 | 2.36 Mn |
| Jun 30, 2025 | 164,000.00 |
| Mar 31, 2025 | -3.62 Mn |
| Dec 31, 2024 | 6.49 Mn |
| Sep 30, 2024 | 3.24 Mn |
| Jun 30, 2024 | -2.20 Mn |
| Mar 31, 2024 | -4.60 Mn |
| Dec 31, 2023 | -6.04 Mn |
| Sep 30, 2023 | -1.85 Mn |
| Jun 30, 2023 | 19.34 Mn |
| Mar 31, 2023 | -3.13 Mn |
| Dec 31, 2022 | -3.74 Mn |
| Sep 30, 2022 | -3.57 Mn |
| Jun 30, 2022 | -5.33 Mn |
| Mar 31, 2022 | -2.29 Mn |
| Dec 31, 2021 | -6.67 Mn |
| Sep 30, 2021 | -4.20 Mn |
| Jun 30, 2021 | -11.24 Mn |
| Mar 31, 2021 | -5.86 Mn |
| Dec 31, 2020 | 318,000.00 |
| Sep 30, 2020 | -4.56 Mn |
| Jun 30, 2020 | -4.19 Mn |
| Mar 31, 2020 | 1.46 Mn |
| Dec 31, 2019 | 291,000.00 |
| Sep 30, 2019 | -3.56 Mn |
| Jun 30, 2019 | -7.74 Mn |
| Mar 31, 2019 | -7.26 Mn |
| Dec 31, 2018 | -5.43 Mn |
| Sep 30, 2018 | -5.32 Mn |
| Jun 30, 2018 | -8.46 Mn |
| Mar 31, 2018 | -7.24 Mn |
| Dec 31, 2017 | -13.31 Mn |
| Sep 30, 2017 | -11.44 Mn |
| Jun 30, 2017 | 450,000.00 |
| Mar 31, 2017 | -59.15 Mn |
| Dec 31, 2016 | -2.44 Mn |
| Sep 30, 2016 | -7.29 Mn |
| Jun 30, 2016 | -10.85 Mn |
| Mar 31, 2016 | -8.60 Mn |
| Dec 31, 2015 | -12.42 Mn |
| Sep 30, 2015 | -3.82 Mn |
| Jun 30, 2015 | -6.18 Mn |
| Mar 31, 2015 | -6.51 Mn |
| Mar 31, 2014 | -7.35 Mn |
| Dec 31, 2013 | -17.83 Mn |
| Sep 30, 2013 | -5.75 Mn |
| Jun 30, 2013 | -6.84 Mn |
| Mar 31, 2013 | -4.32 Mn |
| Dec 31, 2012 | -9.88 Mn |
| Sep 30, 2012 | -5.48 Mn |
| Jun 30, 2012 | 9.64 Mn |
| Mar 31, 2012 | -5.90 Mn |
| Dec 31, 2011 | -8.91 Mn |
| Sep 30, 2011 | -8.88 Mn |
| Jun 30, 2011 | -13.69 Mn |
| Mar 31, 2011 | -5.05 Mn |
| Dec 31, 2010 | -8.53 Mn |
| Sep 30, 2010 | -2.47 Mn |
| Jun 30, 2010 | -10.04 Mn |